Investment
Features
FeesSafety
Academy
More
Pluang+

Compare FedEx Corporation (FDX) vs GeneDx Holdings Corp (WGS) Price & Performance

FedEx CorporationTrade
GeneDx Holdings CorpTrade

Price performance (Past 24H)

Key statistics

FedEx Corporation vs GeneDx Holdings Corp — how do they compare? FedEx Corporation trades at $326.4 (market cap $76.28B), while GeneDx Holdings Corp trades at $82.71 (market cap $2.44B). The key difference: FedEx Corporation is far larger — about 31.3× GeneDx Holdings Corp's market cap, and FedEx Corporation pays a 1.51% dividend while GeneDx Holdings Corp pays none. Which is the better fit depends on your goals.

FDXWGS
Market Cap
$76.28B$2.44B
Sector
IndustrialsTechnology
52-Week High
$338.75$167.51
52-Week Low
$180.51$34.51
Enterprise Value
$105.91B$2.48B
Dividend Yield
1.51%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

FedEx Corporation

FedEx (FDX) trades at $326.25, up 0.36% on the day, with a bullish technical outlook supported by moving averages and a consensus analyst price target of $360.27. Recent earnings beats in Q4 2025 and Q1 2026 highlight strong profitability, with a net income margin of 4.68% and ROE of 14.82%. The company's Network 2.0 initiative aims for $2 billion in annual savings, driving efficiency gains amid a shift to premium logistics services.

The stock offers upside potential from cost-cutting and freight recovery, but faces risks from competitive pressures and economic sensitivity. Analysts are predominantly bullish (57% buy ratings), though elevated RSI levels suggest near-term overbought conditions. Long-term growth hinges on execution of margin improvements and volume normalization in the LTL market.

GeneDx Holdings Corp

GeneDx Holdings Corp (WGS) trades at $82.39, up 5.79% in the past 24 hours, with a bullish technical signal and strong analyst support. The company reported Q2 2026 revenue of $114.4 million, beating guidance, and returned to adjusted profitability earlier than expected. However, net income remains negative at -$106 million for 2026, and the stock faces class action lawsuits with an August 3, 2026 deadline.

Outlook is mixed: bullish technicals and analyst consensus suggest upside to the $90 price target, but fundamental weaknesses and legal risks pose significant challenges. Investment opportunity hinges on sustained revenue growth and margin improvement, while risks include profitability pressures and litigation outcomes.

Returns comparison

Trailing returns across standard periods

About FedEx Corporation

FedEx pioneered overnight delivery in 1973 and remains the world's largest express package provider. In its fiscal 2020 (ended May 2020), FedEx derived 51% of revenue from its express division, 33% from ground, and 10% from freight, its asset-based less-than-truckload shipping segment. The remainder comes from other services, including FedEx Office, which provides document production/shipping, and FedEx Logistics, which provides global forwarding. FedEx acquired Dutch parcel delivery firm TNT Express in 2016. TNT was previously the fourth-largest global parcel delivery provider.

Read more on FDX

About GeneDx Holdings Corp

GeneDx is a patient-centered health intelligence company that specializes in transforming healthcare through the application of genomics. It combines advanced technology with one of the world's largest rare disease genomic datasets to provide clinical-grade exome and genome sequencing, enabling precise and rapid diagnosis for patients with complex medical conditions.

Read more on WGS